Clinical Policy: Teriparatide (Forteo, Bonsity)
Customize your policy alerts
Sign up for QualChoice Policy CP.PCH.62 alerts
Get alerted when Policy CP.PCH.62 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage guidance for teriparatide (Forteo, Bonsity) including dosing, product availability, references, and coding implications for providers and payers adopting QualChoice policy CP.PCH.62.
No material clinical or coverage changes in this revision.
Coverage Criteria and Clinical Guidance
Extracted clinical use guidance
Clinical and product use guidance present in this portion of the policy (not an exhaustive coverage criteria set).
See Appendix D: Dosage and Administration
Lifetime cumulative duration guidance
See Appendix D: Product Availability
Contextual safety information; not an exhaustive contraindication list for teriparatide
Appendix E lists examples of contraindications and adverse effects associated with bisphosphonates (both oral and IV formulations). Key examples include: hypocalcemia (noted for both oral and IV), hypersensitivity to product components, pregnancy, eye inflammation, acute renal failure, osteonecrosis of the jaw, and atypical femoral shaft fracture. Specific formulation-related precautions are also noted, such as inability to stand or sit upright for at least 30 minutes (oral) and reduced creatinine clearance or acute renal impairment (IV). These bisphosphonate contraindications and adverse effects are presented as examples in the policy appendix and do not represent teriparatide-specific contraindications in this section.
Within the coverage criteria section reviewed, there are no explicit statements labeling teriparatide as not medically necessary. The document instead provides clinical guidance and examples of contraindications for other drug classes (e.g., bisphosphonates) without declaring teriparatide to be noncovered or not medically necessary in this portion of the policy.
Billing and Coding
Provider Actions, Prior Auth, and Billing Guidance
Prior authorization and billing codes
Coverage decisions reference HCPCS code J3110 (Injection, teriparatide, 10 mcg) and may reference unclassified drug codes J3490 and C9399 for billing. Obtain prior authorization where required by the Health Plan before initiating therapy and confirm which HCPCS code(s) the plan expects for the submitted product and dose.
Ensure clinical justification and complete documentation
Confirm clinical justification and eligibility per the policy before prescribing teriparatide; ensure documentation supports indication, dosing, and duration limits at the time of prior authorization and claim submission to avoid administrative denials.
- Document indication, dose (20 mcg SC QD where applicable), and planned duration
- Provide clinical rationale if lifetime use may exceed policy-recommended limits
Consult prescribing information and apply HCPCS billing codes
Consult the product prescribing information (Forteo, Bonsity, and manufacturer PI) for FDA‑approved dosing, administration, and safety information and use the HCPCS codes listed in the policy (J3110, J3490, C9399) as billing references when preparing claims.
- Refer to Forteo and Bonsity prescribing information for dosing and administration details
- Use HCPCS J3110 (teriparatide 10 mcg) or applicable unclassified codes as indicated by payer guidance
Coding-based denial risk — verify current coding guidance
Inclusion or exclusion of HCPCS codes in this policy does not guarantee coverage; verify current payer coding guidance and the most up-to-date professional coding resources before submitting claims to reduce the risk of coding‑related denials.
- Policy states codes are for informational purposes only and advises referencing up‑to‑date coding guidance prior to claim submission
Key Definitions and Product Details
Background
Teriparatide is described as an anabolic parathyroid hormone analog used for the treatment of osteoporosis. The policy cites the standard dosing regimen of 20 mcg subcutaneously once daily for indications including postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and male osteoporosis. Product presentations noted in the policy include multi‑dose prefilled pens that contain 28 daily doses. The guidance also references cumulative duration considerations: use beyond a maximum lifetime of 2 years is generally discouraged unless the patient remains at or has returned to a high fracture risk.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.